{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:44:00Z","timestamp":1788821040259,"version":"build-2803163510"},"reference-count":322,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Radiotherapy is one of the most effective and frequently used treatments for a wide range of cancers. In addition to its direct anti-cancer cytotoxic effects, ionising radiation can augment the anti-tumour immune response by triggering pro-inflammatory signals, DNA damage-induced immunogenic cell death and innate immune activation. Anti-tumour innate immunity can result from recruitment and stimulation of dendritic cells (DCs) which leads to tumour-specific adaptive T-cell priming and immunostimulatory cell infiltration. Conversely, radiotherapy can also induce immunosuppressive and anti-inflammatory mediators that can confer radioresistance. Targeting the DNA damage response (DDR) concomitantly with radiotherapy is an attractive strategy for overcoming radioresistance, both by enhancing the radiosensitivity of tumour relative to normal tissues, and tipping the scales in favour of an immunostimulatory tumour microenvironment. This two-pronged approach exploits genomic instability to circumvent immune evasion, targeting both hallmarks of cancer. In this review, we describe targetable DDR proteins (PARP (poly[ADP-ribose] polymerase); ATM\/ATR (ataxia\u2013telangiectasia mutated and Rad3-related), DNA-PKcs (DNA-dependent protein kinase, catalytic subunit) and Wee1 (Wee1-like protein kinase) and their potential intersections with druggable immunomodulatory signalling pathways, including nucleic acid-sensing mechanisms (Toll-like receptors (TLR); cyclic GMP\u2013AMP synthase (cGAS)\u2013stimulator of interferon genes (STING) and retinoic acid-inducible gene-I (RIG-I)-like receptors), and how these might be exploited to enhance radiation therapy. We summarise current preclinical advances, recent and ongoing clinical trials and the challenges of therapeutic combinations with existing treatments such as immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3389\/fonc.2022.971959","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T06:37:33Z","timestamp":1661755053000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Charleen M. L.","family":"Chan Wah Hak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel C.","family":"Patin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan A.","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9131-1","article-title":"Clinical biomarkers and imaging for radiotherapy-induced cell death","volume":"27","author":"Verheij","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0562","article-title":"Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy","volume":"68","author":"Apel","year":"2008","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010102","article-title":"Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization","volume":"17","author":"Maier","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B5","article-title":"The four r\u2019s of radiotherapy","volume-title":"Advances in radiation biology","author":"Withers","year":"1975"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/09553008914552491","article-title":"The 5Rs of radiobiology","volume":"56","author":"Steel","year":"1989","journal-title":"Int J Radiat Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1667\/RR1931.1","article-title":"Links between innate immunity and normal tissue radiobiology","volume":"173","author":"Schaue","year":"2010","journal-title":"Radiat Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4161\/onci.24568","article-title":"ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy","volume":"2","author":"Ma","year":"2013","journal-title":"Oncoimmunology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22197","article-title":"Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting","volume":"2","author":"Kono","year":"2013","journal-title":"Oncoimmunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00588","article-title":"Molecular and translational classifications of DAMPs in immunogenic cell death","volume":"6","author":"Garg","year":"2015","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.01.045","article-title":"Immunological markers that predict radiation toxicity","volume":"368","author":"Sprung","year":"2015","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802967200","article-title":"Oxidative stress promotes ligand-independent and enhanced ligand-dependent tumor necrosis factor receptor signaling","volume":"283","author":"Ozsoy","year":"2008","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00090","article-title":"Regulatory T cells in radiotherapeutic responses","volume":"2","author":"Schaue","year":"2012","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2020-0448","article-title":"Promoting reactive oxygen species generation: a key strategy in nanosensitizer-mediated radiotherapy","volume":"16","author":"Jia","year":"2021","journal-title":"Nanomed (Lond)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/path.5232","article-title":"The immunological consequences of radiation-induced DNA damage","volume":"247","author":"Wilkins","year":"2019","journal-title":"J Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0134","article-title":"Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells","volume":"6","author":"Rudqvist","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2004.06.006","article-title":"Inflammation as a tumor promoter in cancer induction","volume":"14","author":"Philip","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31537","article-title":"A cytokine-mediated link between innate immunity, inflammation, and cancer","volume":"117","author":"Lin","year":"2007","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.04.003","article-title":"Inflammation-associated cancer: NF-kappaB is the lynchpin","volume":"26","author":"Li","year":"2005","journal-title":"Trends Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.12280","article-title":"A systemic complete response of metastatic melanoma to local radiation and immunotherapy","volume":"5","author":"Hiniker","year":"2012","journal-title":"Transl Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20794","article-title":"Radiotherapy augments the immune response to prostate cancer in a time-dependent manner","volume":"68","author":"Harris","year":"2008","journal-title":"Prostate"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00489","article-title":"Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression","volume":"5","author":"Laoui","year":"2014","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1667\/RR0978.1","article-title":"Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice","volume":"173","author":"Qu","year":"2010","journal-title":"Radiat Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","article-title":"Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming","volume":"76","author":"Rodriguez-Ruiz","year":"2016","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9330","article-title":"ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume":"7","author":"Hsieh","year":"2022","journal-title":"Sci Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60241-X","article-title":"Tumour immunity: effector response to tumour and role of the microenvironment","volume":"371","author":"Mantovani","year":"2008","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.12.068","article-title":"Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients","volume":"82","author":"Finkelstein","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B47","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1748-717X-7-59","article-title":"Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced","volume":"7","author":"Hellevik","year":"2012","journal-title":"Radiat Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1633","article-title":"Pancreatic stellate cells radioprotect pancreatic cancer cells through \u03b21-integrin signaling","volume":"71","author":"Mantoni","year":"2011","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.12.041","article-title":"Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-Dependent manner","volume":"17","author":"Erez","year":"2010","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.aan8247","article-title":"Hypoxic cancer-associated fibroblasts increase NCBP2-AS2\/HIAR to promote endothelial sprouting through enhanced VEGF signaling","volume":"12","author":"Kugeratski","year":"2019","journal-title":"Sci Signal"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e7965","DOI":"10.1371\/journal.pone.0007965","article-title":"Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model","volume":"4","author":"Liao","year":"2009","journal-title":"PloS One"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.292","article-title":"Extracellular adenosine triphosphate and adenosine in cancer","volume":"29","author":"Stagg","year":"2010","journal-title":"Oncogene"},{"key":"B56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-016-0154-9","article-title":"Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape","volume":"4","author":"Montalb\u00e1n Del Barrio","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1320011","article-title":"CD39\/CD73 upregulation on myeloid-derived suppressor cells via TGF-\u03b2-mTOR-HIF-1 signaling in patients with non-small cell lung cancer","volume":"6","author":"Li","year":"2017","journal-title":"Oncoimmunology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1178025","article-title":"The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by m-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27","volume":"5","author":"d'Almeida","year":"2016","journal-title":"Oncoimmunology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900475","article-title":"Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness","volume":"183","author":"Hilchey","year":"2009","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2405","article-title":"Autocrine adenosine regulates tumor polyfunctional CD73(+)CD4(+) effector T cells devoid of immune checkpoints","volume":"78","author":"Gourdin","year":"2018","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1650","article-title":"Repopulation of cancer cells during therapy: an important cause of treatment failure","volume":"5","author":"Kim","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2385","article-title":"Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy","volume":"17","author":"Huang","year":"2011","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semcancer.2014.07.001","article-title":"Cancer stem cells, cancer cell plasticity and radiation therapy","volume":"31","author":"Vlashi","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/bcr2479","article-title":"Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment","volume":"12","author":"Lagadec","year":"2010","journal-title":"Breast Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA Damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00113","article-title":"DNA Double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy","volume":"3","author":"Mladenov","year":"2013","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111671","article-title":"Necessities in the processing of DNA double strand breaks and their effects on genomic instability and cancer","volume":"11","author":"Iliakis","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM And ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/science.1140321","article-title":"ATM And ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130445","article-title":"Inhibition of the ATM\/Chk2 axis promotes cGAS\/STING signaling in ARID1A-deficient tumors","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/25.9.1678","article-title":"Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-transcriptional regulation of ATM gene expression","volume":"25","author":"Savitsky","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/258427a0","article-title":"Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity","volume":"258","author":"Taylor","year":"1975","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.18.6521-6532.2002","article-title":"Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner","volume":"22","author":"Hirao","year":"2002","journal-title":"Mol Cell Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)97825-L","article-title":"Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay","volume":"55","author":"Powell","year":"1995","journal-title":"Cancer Res"},{"key":"B78","article-title":"The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage","volume":"56","author":"Price","year":"1996","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4161\/cc.11.6.19576","article-title":"Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control","volume":"11","author":"Golding","year":"2012","journal-title":"Cell Cycle"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0707","article-title":"Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer","volume":"12","author":"Batey","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29121","article-title":"Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019","volume":"136","author":"Vecchio","year":"2015","journal-title":"Int J Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3109\/09553002.2015.1001531","article-title":"The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect","volume":"91","author":"Zhang","year":"2015","journal-title":"Int J Radiat Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28680","article-title":"Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019","volume":"135","author":"Vecchio","year":"2014","journal-title":"Int J Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0761","article-title":"Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004306","article-title":"Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade","volume":"10","author":"Patin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/1541-7786.MCR-21-0725","article-title":"DNA-PK inhibition and radiation promote anti-tumoral immunity through RNA polymerase III in pancreatic cancer","volume":"20","author":"Wang","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1638207","article-title":"Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition","volume":"8","author":"Patel","year":"2019","journal-title":"Oncoimmunology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","article-title":"Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors","volume":"76","author":"Baird","year":"2016","journal-title":"Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0984","article-title":"Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer","volume":"18","author":"Dewan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15326","article-title":"The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432393","article-title":"Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma","volume":"121","author":"Dovedi","year":"2013","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28711","article-title":"A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models","volume":"135","author":"Adlard","year":"2014","journal-title":"Int J Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7928","article-title":"Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy","volume":"7","author":"Dovedi","year":"2016","journal-title":"Oncotarget"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3081","article-title":"Radiotherapy combined with TLR7\/8 activation induces strong immune responses against gastrointestinal tumors","volume":"6","author":"Sch\u00f6lch","year":"2015","journal-title":"Oncotarget"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.361.11.1","article-title":"Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy","volume":"11","author":"Mason","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0926","article-title":"CpG oligodeoxynucleotide enhances tumor response to radiation","volume":"64","author":"Milas","year":"2004","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21131","article-title":"Successful combination of local CpG-ODN and radiotherapy in malignant glioma","volume":"116","author":"Meng","year":"2005","journal-title":"Int J Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e38111","DOI":"10.1371\/journal.pone.0038111","article-title":"An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy","volume":"7","author":"Zhang","year":"2012","journal-title":"PloS One"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00990","article-title":"RIG-1-Like receptor activation synergizes with intratumoral alpha radiation to induce pancreatic tumor rejection, triple-negative breast metastases clearance, and antitumor immune memory in mice","volume":"10","author":"Domankevich","year":"2020","journal-title":"Front Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev.biochem.66.1.61","article-title":"Replication protein a: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism","volume":"66","author":"Wold","year":"1997","journal-title":"Annu Rev Biochem"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.12.041","article-title":"TopBP1 activates the ATR-ATRIP complex","volume":"124","author":"Kumagai","year":"2006","journal-title":"Cell"},{"key":"B107","article-title":"Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage","volume":"60","author":"Chen","year":"2000","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1101\/gad.851000","article-title":"Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress","volume":"14","author":"Tibbetts","year":"2000","journal-title":"Genes Dev"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3109\/10409238.2012.655374","article-title":"Mechanisms of replication fork protection: a safeguard for genome stability","volume":"47","author":"Errico","year":"2012","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the s phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"S\u00f8rensen","year":"2003","journal-title":"Cancer Cell"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates s and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Xiao","year":"2003","journal-title":"J Biol Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204259","article-title":"Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding","volume":"20","author":"Graves","year":"2001","journal-title":"Oncogene"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin b in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br J Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J Med Chem"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J Med Chem"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J Med Chem"},{"key":"B120","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1535-7163.MCT-16-0239","article-title":"Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei","volume":"16","author":"Dillon","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0823","article-title":"Dual phosphoinositide 3-kinase\/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations","volume":"69","author":"Konstantinidou","year":"2009","journal-title":"Cancer Res"},{"key":"B122","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2014.10.003","article-title":"The fork and the kinase: a DNA replication tale from a CHK1 perspective","volume":"763","author":"Gonz\u00e1lez Besteiro","year":"2015","journal-title":"Mutat Res Rev Mutat Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22198","article-title":"Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics","volume":"119","author":"Chen","year":"2006","journal-title":"Int J Cancer"},{"key":"B125","article-title":"Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor","volume":"2","author":"Bunch","year":"1996","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1037","article-title":"LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms","volume":"14","author":"King","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.10.011","article-title":"The inhibition of PARP but not EGFR results in the radiosensitization of HPV\/p16-positive HNSCC cell lines","volume":"113","author":"G\u00fcster","year":"2014","journal-title":"Radiother Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.tranon.2017.04.002","article-title":"MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis","volume":"10","author":"Suzuki","year":"2017","journal-title":"Transl Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0998","article-title":"CHK1 inhibition radiosensitizes head and neck cancers to paclitaxel-based chemoradiotherapy","volume":"15","author":"Barker","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0492","article-title":"AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies","volume":"7","author":"Zabludoff","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9815-9","article-title":"Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg\/m(2) every 21 days in patients with cancer","volume":"31","author":"Weiss","year":"2013","journal-title":"Invest N Drugs"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor sch 900776 in refractory acute leukemias","volume":"18","author":"Karp","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5788","article-title":"Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2234-6","article-title":"Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours","volume":"72","author":"Seto","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz694","article-title":"DNA-PKcs promotes chromatin decondensation to facilitate initiation of the DNA damage response","volume":"47","author":"Lu","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2005.05.003","article-title":"DNA-PK-dependent phosphorylation of Ku70\/80 is not required for non-homologous end joining","volume":"4","author":"Douglas","year":"2005","journal-title":"DNA Repair (Amst)"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24841","article-title":"DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation","volume":"230","author":"Liu","year":"2015","journal-title":"J Cell Physiol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.03.033","article-title":"Inhibiting DNA-PK(CS) radiosensitizes human osteosarcoma cells","volume":"486","author":"Mamo","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00635","article-title":"DNA-PK as an emerging therapeutic target in cancer","volume":"9","author":"Mohiuddin","year":"2019","journal-title":"Front Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127483","article-title":"Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy","volume":"130","author":"Willoughby","year":"2020","journal-title":"J Clin Invest"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(06)00258-2","article-title":"Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV","volume":"7","author":"Critchlow","year":"1997","journal-title":"Curr Biol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00005","article-title":"Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond","volume":"4","author":"Davidson","year":"2013","journal-title":"Front Pharmacol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208332","article-title":"The life and death of DNA-PK","volume":"24","author":"Collis","year":"2005","journal-title":"Oncogene"},{"key":"B145","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/1476-4598-13-232","article-title":"Targeting DNA-PKcs and telomerase in brain tumour cells","volume":"13","author":"Gurung","year":"2014","journal-title":"Mol Cancer"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1159\/000445551","article-title":"NU7441 enhances the radiosensitivity of liver cancer cells","volume":"38","author":"Yang","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4250","article-title":"DNA-Dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs","volume":"65","author":"Shinohara","year":"2005","journal-title":"Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg753","article-title":"Vanillins\u2013a novel family of DNA-PK inhibitors","volume":"31","author":"Durant","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2431","article-title":"OK-1035, a selective inhibitor of DNA-dependent protein kinase","volume":"215","author":"Take","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207303","article-title":"SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization","volume":"23","author":"Ismail","year":"2004","journal-title":"Oncogene"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2011.03.003","article-title":"Proteomic profiling revealed the functional networks associated with mitotic catastrophe of HepG2 hepatoma cells induced by 6-bromine-5-hydroxy-4-methoxybenzaldehyde","volume":"252","author":"Zhang","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9678-5","article-title":"Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells","volume":"30","author":"Davidson","year":"2012","journal-title":"Invest N Drugs"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0780","article-title":"Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials","volume":"6","author":"Guo","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B154","doi-asserted-by":"publisher","first-page":"18882","DOI":"10.1038\/s41598-019-54796-6","article-title":"Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models","volume":"9","author":"Wise","year":"2019","journal-title":"Sci Rep"},{"key":"B155","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat Commun"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25383","article-title":"VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells","volume":"9","author":"Khan","year":"2018","journal-title":"Oncotarget"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4159","article-title":"Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy","volume":"6","author":"Lamb","year":"2015","journal-title":"Oncotarget"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15153","article-title":"Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0362","article-title":"Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814","volume":"17","author":"Sun","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00047","article-title":"DNA-PK is a DNA sensor for IRF-3-dependent innate immunity","volume":"1","author":"Ferguson","year":"2012","journal-title":"Elife"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba4219","article-title":"Human DNA-PK activates a STING-independent DNA sensing pathway","volume":"5","author":"Burleigh","year":"2020","journal-title":"Sci Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.molcel.2019.06.020","article-title":"Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21","volume":"75","author":"Kim","year":"2019","journal-title":"Mol Cell"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.646638","article-title":"Poly(ADP-ribose) polymerase 1 modulates interaction of the nucleotide excision repair factor XPC-RAD23B with DNA via Poly(ADP-ribosyl)ation","volume":"290","author":"Maltseva","year":"2015","journal-title":"J Biol Chem"},{"key":"B164","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.vph.2010.06.003","article-title":"Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications","volume":"53","author":"Sodhi","year":"2010","journal-title":"Vascul Pharmacol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.10640","article-title":"DNA\u2212PKcs PARylation regulates DNA\u2212PK kinase activity in the DNA damage response","volume":"20","author":"Han","year":"2019","journal-title":"Mol Med Rep"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21300","article-title":"Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1\/2","volume":"8","author":"Vormoor","year":"2017","journal-title":"Oncotarget"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.07.062","article-title":"Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells","volume":"478","author":"Hirai","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3007","article-title":"Strategies to improve radiotherapy with targeted drugs","volume":"11","author":"Begg","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.205054","article-title":"PARP-1-Targeted radiotherapy in mouse models of glioblastoma","volume":"59","author":"Jannetti","year":"2018","journal-title":"J Nucl Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.2174\/187153011797881184","article-title":"Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator","volume":"11","author":"Laudisi","year":"2011","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12099","article-title":"Beyond DNA repair, the immunological role of PARP-1 and its siblings","volume":"139","author":"Rosado","year":"2013","journal-title":"Immunology"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J Clin Invest"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60637","article-title":"PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response","volume":"9","author":"Kim","year":"2020","journal-title":"Elife"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003499117","article-title":"Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency","volume":"117","author":"McLaughlin","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.molcel.2022.03.034","article-title":"Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS","volume":"82","author":"Wang","year":"2022","journal-title":"Mol Cell"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-017-0916-z","article-title":"Nicotinamide inhibits ethanol-induced caspase-3 and PARP-1 over-activation and subsequent neurodegeneration in the developing mouse cerebellum","volume":"17","author":"Ieraci","year":"2018","journal-title":"Cerebellum"},{"key":"B178","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jnci\/djh005","article-title":"Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361","volume":"96","author":"Calabrese","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0418","article-title":"Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the s phase of the cell cycle and involves arrest of DNA synthesis","volume":"5","author":"No\u00ebl","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA Approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4508","article-title":"European Regulators approve first PARP inhibitor","volume":"13","author":"Mullard","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B182","unstructured":"L, a. FDA grants breakthrough designation to niraparib for metastatic CRPC2019"},{"key":"B183","article-title":"FDA Approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer","volume-title":"Drug approvals and databases 2020","year":""},{"key":"B184","article-title":"FDA Approves olaparib tablets for maintenance treatment in ovarian cancer","volume-title":"Drug approvals and databases 2017","year":""},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0042","article-title":"FDA Approval summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy","volume":"24","author":"Ison","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21338","article-title":"The PARP-1 inhibitor olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+\/-) lymphoblastoid cells","volume":"8","author":"Bourton","year":"2017","journal-title":"J Cancer"},{"key":"B187","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.3390\/ijms20236026","article-title":"A small compound KJ-28d enhances the sensitivity of non-small cell lung cancer to radio- and chemotherapy","volume":"20","author":"Ryu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B188","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/1471-2407-14-603","article-title":"PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models","volume":"14","author":"Guillot","year":"2014","journal-title":"BMC Cancer"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9770-x","article-title":"MK-4827, a PARP-1\/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation","volume":"30","author":"Wang","year":"2012","journal-title":"Invest N Drugs"},{"key":"B190","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.canrad.2014.05.012","article-title":"[PARP inhibitors and radiotherapy: rational and prospects for a clinical use]","volume":"18","author":"Pernin","year":"2014","journal-title":"Cancer Radiother"},{"key":"B191","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat Cancer"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1111\/1462-2920.12530","article-title":"Wee1 and Cdc25 control morphogenesis, virulence and multistress tolerance of beauveria bassiana by balancing cell cycle-required cyclin-dependent kinase 1 activity","volume":"17","author":"Qiu","year":"2015","journal-title":"Environ Microbiol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"110310","DOI":"10.1016\/j.cellsig.2022.110310","article-title":"The expanding role of WEE1","volume":"94","author":"Koh","year":"2022","journal-title":"Cell Signal"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1894","article-title":"WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition","volume":"74","author":"Hamilton","year":"2014","journal-title":"Cancer Res"},{"key":"B195","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s13046-021-02120-4","article-title":"Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS\/STING signaling in gastric cancer cells","volume":"40","author":"Li","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15108","article-title":"WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade","volume":"112","author":"Wu","year":"2021","journal-title":"Cancer Sci"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1627","article-title":"Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy","volume":"26","author":"Hai","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210789","article-title":"WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway","volume":"219","author":"Guo","year":"2022","journal-title":"J Exp Med"},{"key":"B199","doi-asserted-by":"publisher","first-page":"15394","DOI":"10.1038\/s41598-019-51959-3","article-title":"Anti-tumor effects of Wee1 kinase inhibitor with radiotherapy in human cervical cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0692","article-title":"Quantitative phosphoproteomics reveals Wee1 kinase as a therapeutic target in a model of proneural glioblastoma","volume":"15","author":"Lescarbeau","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00725","article-title":"A WEE1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells","volume":"11","author":"Matheson","year":"2016","journal-title":"ACS Chem Biol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.09.006","article-title":"Sensitization of pancreatic cancers to gemcitabine chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair","volume":"17","author":"Kausar","year":"2015","journal-title":"Neoplasia"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.09.123","article-title":"Specific inhibition of Wee1 kinase and Rad51 recombinase: a strategy to enhance the sensitivity of leukemic T-cells to ionizing radiation-induced DNA double-strand breaks","volume":"453","author":"Havelek","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"B204","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2407-11-156","article-title":"WEE1 inhibition sensitizes osteosarcoma to radiotherapy","volume":"11","author":"PosthumaDeBoer","year":"2011","journal-title":"BMC Cancer"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0650","article-title":"MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells","volume":"17","author":"Bridges","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1511700","article-title":"Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy","volume":"27","author":"Fu","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.297","article-title":"Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"B208","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molcel.2013.01.039","article-title":"STING recognition of cytoplasmic DNA instigates cellular defense","volume":"50","author":"Abe","year":"2013","journal-title":"Mol Cell"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900850106","article-title":"ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization","volume":"106","author":"Sun","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215006109","article-title":"STING manifests self DNA-dependent inflammatory disease","volume":"109","author":"Ahn","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00896","article-title":"Activation of STING by cGAMP regulates MDSCs to suppress tumor metastasis via reversing epithelial-mesenchymal transition","volume":"10","author":"Cheng","year":"2020","journal-title":"Front Oncol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-019-0302-0","article-title":"STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Death Differ"},{"key":"B217","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA Exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01018-0","article-title":"Antivascular therapy of cancer: DMXAA","volume":"4","author":"Baguley","year":"2003","journal-title":"Lancet Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.529128","article-title":"Temporal aspects of the action of ASA404 (vadimezan; DMXAA)","volume":"19","author":"Baguley","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600368","article-title":"Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid","volume":"86","author":"Ching","year":"2002","journal-title":"Br J Cancer"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00358-7","article-title":"Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid","volume":"42","author":"Wilson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1711.2006.01448.x","article-title":"5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy","volume":"84","author":"Matthews","year":"2006","journal-title":"Immunol Cell Biol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING promotes the growth of tumors characterized by low antigenicity via IDO activation","volume":"76","author":"Lemos","year":"2016","journal-title":"Cancer Res"},{"key":"B224","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat Commun"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J Clin Invest"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001906","article-title":"STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment","volume":"9","author":"Chelvanambi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B228","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"B231","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1038\/s41467-019-13094-5","article-title":"An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"B232","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1158\/1538-7445.AM2020-6706","article-title":"Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines","author":"Raghida","year":"2020","journal-title":"Cancer Res"},{"key":"B233","doi-asserted-by":"publisher","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","article-title":"Trial watch: STING agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"B234","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/jid.2012.288","article-title":"TLR signaling and DNA repair: are they associated","volume":"133","author":"Harberts","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001360","article-title":"The toll-like receptor gene family is integrated into human DNA damage and p53 networks","volume":"7","author":"Menendez","year":"2011","journal-title":"PloS Genet"},{"key":"B236","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2020.04.020","article-title":"Toll-like receptor agonists and radiation therapy combinations: An untapped opportunity to induce anticancer immunity and improve tumor control","volume":"108","author":"Walshaw","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.2.373","article-title":"Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites","volume":"188","author":"Dieu","year":"1998","journal-title":"J Exp Med"},{"key":"B238","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0092-8674(00)80059-8","article-title":"CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs","volume":"99","author":"F\u00f6rster","year":"1999","journal-title":"Cell"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N","article-title":"Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation","volume":"28","author":"Sallusto","year":"1998","journal-title":"Eur J Immunol"},{"key":"B240","volume-title":"Immunobiology: The immune system in health and disease","author":"Janeway","year":"2001"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1126\/science.1078231","article-title":"Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells","volume":"299","author":"Pasare","year":"2003","journal-title":"Science"},{"key":"B242","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.vaccine.2005.01.115","article-title":"IFN-alpha\/beta-dependent cross-priming induced by specific toll-like receptor agonists","author":"Durand","year":"2006","journal-title":"Vaccine"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.9.6122","article-title":"Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN","volume":"177","author":"McBride","year":"2006","journal-title":"J Immunol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4102","article-title":"A subset of toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells","volume":"170","author":"Datta","year":"2003","journal-title":"J Immunol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1038\/nature03326","article-title":"Toll-like receptor 3 promotes cross-priming to virus-infected cells","volume":"433","author":"Schulz","year":"2005","journal-title":"Nature"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2010.05.008","article-title":"Double stranded RNA- relative to other TLR ligand-activated dendritic cells induce extremely polarized human Th1 responses","volume":"264","author":"Benwell","year":"2010","journal-title":"Cell Immunol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404763","article-title":"Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells","volume":"21","author":"Smits","year":"2007","journal-title":"Leukemia"},{"key":"B248","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4049\/jimmunol.163.1.57","article-title":"Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells","volume":"163","author":"Verdijk","year":"1999","journal-title":"J Immunol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.013","article-title":"The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na\u00efve recipient mice","volume":"27","author":"Salem","year":"2009","journal-title":"Vaccine"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.3.1535","article-title":"Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors","volume":"180","author":"Currie","year":"2008","journal-title":"J Immunol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2006.08.004","article-title":"The direct effects of toll-like receptor ligands on human NK cell cytokine production and cytotoxicity","volume":"241","author":"Lauzon","year":"2006","journal-title":"Cell Immunol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.138","article-title":"APC-independent activation of NK cells by the toll-like receptor 3 agonist double-stranded RNA","volume":"172","author":"Schmidt","year":"2004","journal-title":"J Immunol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901500","article-title":"Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways","volume":"183","author":"Miyake","year":"2009","journal-title":"J Immunol"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113099109","article-title":"Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors","volume":"109","author":"Shime","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01650","article-title":"TLR-3 stimulation skews M2 macrophages to M1 through IFN-\u03b1\u03b2 signaling and restricts tumor progression","volume":"9","author":"Vidyarthi","year":"2018","journal-title":"Front Immunol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13543","article-title":"Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model","volume":"109","author":"Yoshida","year":"2018","journal-title":"Cancer Sci"},{"key":"B257","article-title":"Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-l-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer","volume":"39","author":"Levine","year":"1979","journal-title":"Cancer Res"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"B259","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature08512","article-title":"HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses","volume":"462","author":"Yanai","year":"2009","journal-title":"Nature"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq071","article-title":"A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma","volume":"12","author":"Rosenfeld","year":"2010","journal-title":"Neuro Oncol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9693-3","article-title":"A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a north American brain tumor consortium (NABTC01-05)","volume":"91","author":"Butowski","year":"2009","journal-title":"J Neurooncol"},{"key":"B262","doi-asserted-by":"publisher","first-page":"e1230578","DOI":"10.1080\/2162402X.2016.1230578","article-title":"TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function","volume":"5","author":"Spinetti","year":"2016","journal-title":"Oncoimmunology"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402004","article-title":"Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells","volume":"194","author":"Wang","year":"2015","journal-title":"J Immunol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.5.2476","article-title":"Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod","volume":"174","author":"Rechtsteiner","year":"2005","journal-title":"J Immunol"},{"key":"B265","first-page":"9","article-title":"The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand","volume":"4","author":"Shackleton","year":"2004","journal-title":"Cancer Immun"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl046","article-title":"Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists","volume":"18","author":"Gorski","year":"2006","journal-title":"Int Immunol"},{"key":"B267","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5070\/D34VW339W4","article-title":"Imiquimod 5 percent cream and the treatment of cutaneous malignancy","volume":"10","author":"Navi","year":"2004","journal-title":"Dermatol Online J"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113401","article-title":"Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function","volume":"309","author":"Peng","year":"2005","journal-title":"Science"},{"key":"B269","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/gb-2007-8-1-r8","article-title":"Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection","volume":"8","author":"Panelli","year":"2007","journal-title":"Genome Biol"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1080\/15257770701490472","article-title":"Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine","volume":"26","author":"Xiang","year":"2007","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B271","volume-title":"Anadys Pharmaceuticals Discontinues Development of Hepatitis C Drug [press release]","year":"2007"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1038\/35047123","article-title":"A toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct b-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.24.6973","article-title":"Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells","volume":"18","author":"H\u00e4cker","year":"1999","journal-title":"EMBO J"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.16.9305","article-title":"CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells","volume":"96","author":"Hartmann","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B277","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.161.6.3042","article-title":"Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA","volume":"161","author":"Jakob","year":"1998","journal-title":"J Immunol"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8","article-title":"Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells","volume":"28","author":"Sparwasser","year":"1998","journal-title":"Eur J Immunol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101304","article-title":"Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells","volume":"188","author":"Shirota","year":"2012","journal-title":"J Immunol"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2628","article-title":"Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of toll-like receptor 9","volume":"15","author":"Aurisicchio","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B282","article-title":"Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides","volume":"9","author":"Baines","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.1217","article-title":"Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients","volume":"98","author":"Blazar","year":"2001","journal-title":"Blood"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.8.3941","article-title":"Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity","volume":"171","author":"Lonsdorf","year":"2003","journal-title":"J Immunol"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.5247","article-title":"NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides","volume":"167","author":"Kawarada","year":"2001","journal-title":"J Immunol"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J Clin Oncol"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat Immunol"},{"key":"B288","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mib.2014.05.004","article-title":"An evolving arsenal: viral RNA detection by RIG-i-like receptors","volume":"20","author":"Fitzgerald","year":"2014","journal-title":"Curr Opin Microbiol"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2012.10.005","article-title":"MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells","volume":"2","author":"Feng","year":"2012","journal-title":"Cell Rep"},{"key":"B290","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41467-021-22484-7","article-title":"Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling","volume":"12","author":"Guo","year":"2021","journal-title":"Nat Commun"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049158","article-title":"Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice","volume":"51","author":"Poeck","year":"2021","journal-title":"Eur J Immunol"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37155","article-title":"Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells","volume":"119","author":"Besch","year":"2009","journal-title":"J Clin Invest"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3850","article-title":"Therapeutic efficacy of bifunctional siRNA combining TGF-\u03b21 silencing with RIG-I activation in pancreatic cancer","volume":"73","author":"Ellermeier","year":"2013","journal-title":"Cancer Res"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0825","article-title":"Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells","volume":"70","author":"K\u00fcbler","year":"2010","journal-title":"Cancer Res"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.96","article-title":"RIG-i-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells","volume":"21","author":"Duewell","year":"2014","journal-title":"Cell Death Differ"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0129-T","article-title":"RIG-I resists hypoxia-induced immunosuppression and dedifferentiation","volume":"5","author":"Engel","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B298","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-016-0471-3","article-title":"RNA Virus receptor rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer","volume":"36","author":"Zhu","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8420","article-title":"Cancer therapies activate RIG-i-like receptor pathway through endogenous non-coding RNAs","volume":"7","author":"Ranoa","year":"2016","journal-title":"Oncotarget"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190801","article-title":"Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses","volume":"216","author":"Jiang","year":"2019","journal-title":"J Exp Med"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.2174\/1568009620666200115161717","article-title":"Fas ligand enhances apoptosis of human lung cancer cells cotreated with RIG-i-like receptor agonist and radiation","volume":"20","author":"Sato","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"B302","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B304","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13621","article-title":"Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer","volume":"11","author":"Matiello","year":"2020","journal-title":"Thorac Cancer"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2019.11.017","article-title":"The association between total lymphocyte count after concomitant chemoradiation and overall survival in patients with newly diagnosed glioblastoma","volume":"71","author":"Ahn","year":"2020","journal-title":"J Clin Neurosci"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.11.063","article-title":"Beware of clinical trials of DNA repair inhibitors","volume":"103","author":"Brown","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B311","doi-asserted-by":"publisher","first-page":"viii649","DOI":"10.1093\/annonc\/mdy303.015","article-title":"Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: results from two phase I trials, in ESMO 2017 congress. 2018","volume":"29","author":"Mau-Sorensen","year":"2018","journal-title":"Annals of Oncology"},{"key":"B312","doi-asserted-by":"publisher","first-page":"113641","DOI":"10.1016\/j.bcp.2019.113641","article-title":"Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361","volume":"169","author":"Wong","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"B313","article-title":"Hypoxia-selective DNA-PK inhibitor [abstract]","volume-title":"AACR-NCI-EORTC international conference","author":"Alastair","year":"2017"},{"key":"B314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.08.021","article-title":"Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation","volume":"3","author":"Ko","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B317","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1017\/erm.2022.6","article-title":"Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair","volume":"24","author":"Nikitaki","year":"2022","journal-title":"Expert Rev Mol Med"},{"key":"B318","doi-asserted-by":"publisher","first-page":"11047","DOI":"10.3390\/ijms222011047","article-title":"Role of mitochondria in radiation responses: Epigenetic, metabolic, and signaling impacts","volume":"22","author":"Averbeck","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03269-w","article-title":"Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance","volume":"591","author":"Tigano","year":"2021","journal-title":"Nature"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0751-0","article-title":"Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy","volume":"21","author":"Yamazaki","year":"2020","journal-title":"Nat Immunol"},{"key":"B321","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.trsl.2018.07.014","article-title":"Mitochondria in innate immune signaling","volume":"202","author":"Banoth","year":"2018","journal-title":"Transl Res"},{"key":"B322","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2017.11.011","article-title":"Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment","volume":"26","author":"Chang","year":"2018","journal-title":"Mol Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.971959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:52:57Z","timestamp":1676533977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.971959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":322,"alternative-id":["10.3389\/fonc.2022.971959"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.971959","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"article-number":"971959"}}